Notícias Nurexone Biologic Inc - NRX | Ações TSX Venture Exchange | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
Canadá
TSXV
Nurexone Biologic Inc (NRX)
Nurexone Biologic Inc (NRX) Notícias

Nurexone Biologic Inc (NRX)

0,63

0,02

(3,28%)

Fechado 15 Fevereiro 6:00PM

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer

Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma

Updates from NurExone: Growth Conference Presentation and Website Relaunch

NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market

On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development

NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application

NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders

NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials

NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations

NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility

NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine

NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update

Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise

In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN

NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

1
2
Próxima

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Nurexone Biologic

Exchange Traded Fund Inv...

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições